

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA of ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma)

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Stakeholders commented that recruitment for clinical trials for ERC1671 has been restricted to adults with a Karnofsky performance status of ≥ 70 (at assessment) which is defined as “cares for self; unable to carry on normal activity or to do active work”. They noted that, due to the location of the tumour, individuals with a glioblastoma may rapidly deteriorate below a performance status of 70, thereby excluding them participating in the trial. They also noted that, as mentioned in the scope document, treatment decisions take into account Karnofsky performance status; therefore, it is important that any assessment of clinical and cost effectiveness consider the impact on all patients.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The scope population is not limited by Karnofsky status, so this is not considered to be an equalities issue at this point. The generalisability of the trial population to the scope population will be considered by the appraisal committee. The committee will be aware of the need to secure equality of access for treatments for people with disabilities.

3. Has any change to the draft scope been agreed to highlight potential

equality issues?
No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name):Janet Robertson.....

Date: 27 November 2019